Maxygen Announces Positive Results of MAXY-G34 Phase IIa Study in Breast Cancer Patients
News Jul 15, 2009
Maxygen, Inc. has announced the completion of a Phase IIa clinical study in breast cancer patients in which MAXY-G34 was safe and effective in reducing chemotherapy-induced neutropenia (CIN), a major side effect of myelosuppressive anti-cancer agents.
“We are encouraged by these clinical data and FDA feedback on Maxygen’s proposed development plan for MAXY-G34 in CIN,” said Russell Howard, Maxygen’s Chief Executive Officer.
“These events further confirm that, with the right partnership, a timely and cost effective development pathway to BLA filing can be achieved in 2013. MAXY-G34, with a product profile similar to Neulasta®, could be the 2nd entrant in the multi-billion dollar, long-acting G-CSF market.”
The objectives of this recently completed Phase IIa study were to evaluate safety, tolerability, pharmacokinetics and efficacy of MAXY-G34 in breast cancer patients.
The 35 patient trial included 27 patients receiving MAXY-G34 (doses of 10, 30, 45, 60 or 100 µg/kg) and 8 patients receiving Neulasta® (fixed dose of 6 mg). Both study medications were administered as a single, subcutaneous injection 24 hours post chemotherapy. A highly myelosuppressive TAC chemotherapy regimen was used in the trial.
In the absence of G-CSF treatment, TAC chemotherapy is expected to induce 7-8 days of severe neutropenia [Nabholtz et al, Phase II Study of Docetaxel, Doxorubicin and Cyclophosphamide as First-line Chemotherapy for Metastatic Breast Cancer, Journal of Clinical Oncology (2001)]. The primary efficacy endpoint of the study was duration of severe neutropenia in chemotherapy cycle 1.
In this clinical study, all doses of MAXY-G34 effectively reduced the duration of severe neutropenia (DSN) observed, compared to the above-referenced historical controls. Importantly, no MAXY-G34 patients required rescue therapy due to insufficient efficacy of MAXY-G34.
The mean duration of severe neutropenia for MAXY-G34 dose groups in chemotherapy cycle 1 ranged from 0.8 to 2.2 days, versus 2.0 days in the Neulasta® control group. Data on the primary efficacy endpoint for the MAXY-G34 doses in the range proposed for further study and the Neulasta® control group are included below:
MAXY-G34 was also safe and well-tolerated in this clinical study. The type and incidence of adverse events were consistent with those observed in other G-CSF clinical trials and were comparable between the MAXY-G34 and Neulasta® treatment arms.
No dose relationship was observed with respect to adverse events in the MAXY-G34 groups. No unexpected serious adverse events were noted in any patients. No immunogenicity was detected after six administrations of MAXY-G34 at any dose level.
Maxygen submitted the Phase IIa data as part of a scientific advice briefing package to the United States Food & Drug Administration (FDA) to solicit feedback on key elements of the MAXY-G34 development plan, including:
• Design of the Phase IIb trial;
• Dose selection for the Phase IIb trial; and
• Scope of clinical development required to support a broad indication label.
The FDA’s written response provides a clear development path for MAXY-G34 to achieve a broad label indication for chemotherapy-induced neutropenia. FDA provided feedback on Maxygen’s Phase IIb study proposal, Phase III plan and overall scope of development anticipated to support a Biologic License Application (BLA). This feedback leads Maxygen to conclude that a potential timely and cost effective path to BLA filing for MAXY-G34 in CIN can be achieved.
Scientists working in a range of disciplines joined forces to identify a new approach to combat African sleeping sickness. Their research revealed a promising strategy to develop a suitable agent. This novel concept could also be employed in the future rational design of drugs for the treatment of other diseases.READ MORE
15th International Conference on Surgical Pathology and Cancer Diagnosis
Apr 15 - Apr 16, 2019